Adaptimmune Therapeutics plc, a commercial-stage biopharmaceutical company, provides novel cell therapies primarily to cancer patients in the United States and the United Kingdom. It develops TECELRA ((famitresgene autoleucel or afami-cel), a genetically modified autologous T-cell immunotherapy for the treatment of adults with unresectable or metastatic synovial sarcoma; Lete-cel for the treatment synovial sarcoma and myxoid liposarcoma; and ADP-5701, which is in Phase 1 clinical trial for the treatment of head and neck cancer. The company also focuses on the development of T-cell therapies directed to PRAME (ADP-600) and CD70 (ADP-520). It has strategic collaboration with Galapagos to clinical proof-of-concept trial to evaluate the safety and efficacy of uza-cel produced on Galapagos' decentralized manufacturing platform (ADP-5701) in patients with head and neck cancer; collaboration and license agreement with Noile-Immune Biotech, Inc. and strategic alliance agreement with the MD Anderson Cancer Center. Adaptimmune Therapeutics plc was founded in 2008 and is headquartered in Abingdon, the United Kingdom. Show more

Location: 60 Jubilee Avenue, Abingdon, OX14 4RX, United Kingdom | Website: https://www.adaptimmune.com | Industry: Biotechnology | Sector: Healthcare

Market Cap

64.94M

52 Wk Range

$0.20 - $1.48

Previous Close

$0.24

Open

$0.24

Volume

557,185

Day Range

$0.24 - $0.25

Enterprise Value

378.8M

Cash

59.56M

Avg Qtr Burn

-26.96M

Insider Ownership

0.63%

Institutional Own.

44.16%

Qtr Updated

03/31/25

Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
TECELRA (afamitresgene autoleucel) Details Cancer, Synovialsarcoma	Approved Quarterly sales	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Lete-cel (NY-ESO) Details Myxoid/Round cell liposarcoma, Sarcoma	BLA Submission	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Uzatresgene autoleucel (uza-cel)(ADP-A2M4CD8) (MAGE A4) +/- nivolumab Details Head and neck cancer, Bladder cancer, Cancer, Solid tumor/s, Urothelial cancer	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
afami-cel (afamitresgene autoleucel) (ADP-A2M4) + pembro Details Head and neck cancer, Homozygous familial hypercholesterolemia, Cancer, Solid tumor/s	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
TC-110 (CD19) Details Non-Hodgkin lymphoma, Leukemia, Acute lymphoblastic leukemia, Diffuse large B cell lymphoma, Cancer	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
ADP-A2AFP Details Hepatocellular carcinoma, Cancer	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Gavo-cel (TC-210) (Mesothelin) + nivolumab Details Solid tumor/s, Ovarian cancer, Cancer	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
TC-510 Details Cancer, Colorectal cancer , Ovarian cancer, Mesothelioma, Triple-negative breast cancer , Pancreatic cancer	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Uzatresgene autoleucel /uza-cel (ADP-A2M4CD8 )(MAGE A4) +/- nivolumab Details Cancer, Ovarian cancer	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.